Modified protein
Modified CBMs address the immune response issues of protein therapeutics by reducing immunogenicity and enhancing stability, improving therapeutic efficacy and safety.
Patent Information
- Application Number
- JP2024124909
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2018-01-09
- Filing Date
- 2024-07-31
- Publication Date
- 2024-11-21
AI Technical Summary
Protein-based therapeutics face adverse immune responses due to the risk of anti-drug antibody formation, leading to reduced efficacy and potential hypersensitivity reactions, which is a challenge in using sialic acid-linked carbohydrate binding modules (CBMs) like Sp2CBMTD.
Modification of CBMs, such as CBM40, through mutations to reduce immunogenicity and alter antigenicity, enhancing thermal stability and solubility, and increasing in vivo half-life, while maintaining sialic acid binding capability.
The modified CBMs demonstrate reduced immunogenicity, improved therapeutic efficacy, and enhanced stability, minimizing adverse reactions and extending half-life, as shown in in vitro and in vivo studies.
Smart Images

Figure 2024163117000001_ABST
Abstract
Description
[Technical field]
[0001] The present invention provides novel sialic acid binding molecules and uses (including medical uses) of same. [Background technology]
[0002] Sialic acid-binding carbohydrate-binding modules (CBMs), including those from Vibrio cholerae and Streptococcus pneumoniae and their multivalent forms, have been shown to be effective antibacterial agents, and some have been shown to protect mice from lethal challenge with H7N9 influenza virus. The biologic, Sp2CBMTD, contains two copies of the CBM family 40 domain of S. pneumoniae neuraminidase A (SpCBM) genetically fused to the trimerization domain of Pseudomonas aeruginosa pseudoaminidase (PaTD). The proteins assemble via the trimerization domain to form oligomers containing six copies of SpCBM. However, with any protein-based therapeutic, there is a risk of adverse effects associated with the patient's immune response to the biologic. In some cases, biologics may induce the production of anti-drug antibodies (ADAs) that may result in the formation of immune complexes (ICs) between the ADAs and the drug. The presence of such complexes may reduce efficacy or alter the half-life of the therapeutic, or may cause adverse effects such as hypersensitivity reactions. There are many factors that influence the immunogenicity of proteins. One important determinant is the presence of unique epitopes that can trigger T cell-dependent events leading to antibody production. T cells recognize short peptide fragments derived from the processing of protein antigens occurring within antigen-presenting cells (APCs). Some of these fragments will form complexes with human leukocyte antigen (HLA) / major histocompatibility complex (MHC) class II molecules and, if sufficiently stably bound, will be delivered to the surface of APCs and presented to T cells. Recognition of non-self peptides by T cell receptors triggers the ensuing immune response. Summary of the Invention
[0003] The present disclosure provides a novel group of sialic acid binding molecules. The sialic acid binding molecules described herein may contain one or more engineered carbohydrate binding modules (CBMs). As stated, with any protein-based therapeutic, there is a risk of adverse effects associated with the patient's immune response to the biologic. Biologics may also induce the production of anti-drug antibodies (ADAs), which may result in the formation of immune complexes (ICs) between the ADAs and the drug. The presence of such complexes may reduce efficacy or alter the half-life of the therapeutic, or may cause adverse effects such as hypersensitivity reactions. The CBM of the present disclosure has been modified to reduce the risk of such adverse effects.
[0004] Carbohydrate binding modules are classified into families, and CBMs classified as members of Family 40 CBM (CBM40) may be useful in producing the engineered molecules described herein. Family 40 CBMs contain molecules of approximately 200 residues and are often found at the N-terminus of GH33 sialidases. They may be found inserted into the β-propeller of GH33 sialidases. Thus, the sialic acid binding molecules described herein may comprise one or more modified Family 40 carbohydrate binding modules (CBM40). Throughout this specification, the term "comprising" is used to indicate that an embodiment "includes" the mentioned features, and may thus include other features. However, the term "comprising" can also encompass embodiments "consisting essentially of" or "consisting of" the relevant features.
[0005] In view of the above, the present disclosure may include molecules that include a sialic acid binding element, e.g., a larger molecule that includes a sialic acid binding element. As noted, the sialic acid binding element (i.e., the sialic acid binding molecule) itself may include (consist of, or consist essentially of) a modified CBM, e.g., modified CBM40. By way of (non-limiting) example, the molecules of the present disclosure may not only exhibit the ability to bind sialic acid, but may also have one or more other functions. For example, the molecules may have enzymatic activity. For example, a useful molecule may include a modified CBM (as described herein) and exhibit some sialidase activity. In one embodiment, the CBM may not be provided as part of or contained within a molecule that has enzymatic (eg, sialidase) activity. Useful sialic acid binding molecules may be fusion proteins comprising an enzyme portion and a sialic acid binding portion, where the sialic acid binding portion comprises a modified CBM as described herein. In such cases, the enzyme portion may be fused to the sialic acid binding portion. As noted, the enzyme portion of any useful fusion protein may comprise (or have or exhibit) sialidase activity. The term "modified" encompasses molecules that contain one or more mutations relative to a reference sequence.
[0006] A "reference sequence" may be any wild-type CBM sequence. For example, a reference sequence may comprise, consist essentially of, or consist of a wild-type Family 40 CBM sequence, such as the wild-type CBM sequence of Vibrio cholerae NanH sialidase or Streptococcus pneumoniae NanA sialidase (it should be recognized that similar or matching CBMs present in other microorganisms, including CBM40, are encompassed within the scope of the term "CBM" and / or CBM reference sequence). Thus, the modified CBM sequence may be derived from a given or particular wild-type CBM. The modified CBM sequence may comprise a wild-type CBM sequence containing one or more mutations.
[0007] The one or more mutations may be functional, i.e., they may individually (and / or independently) or collectively (e.g., synergistically) modulate (alter, enhance, or suppress / inhibit) one or more physiological, biological, immunological and / or pharmacological properties of the wild-type CBM (e.g., the wild-type CBM from which the modified CBM is derived). In particular, the one or more mutations may be: (i) the immunogenicity (or antigenicity) of the CBM may be altered; and / or (ii) the potency (of the CBM or any multimeric molecule comprising the modified CBM) may be altered (e.g., improved); and / or (iii) they may modulate (e.g., enhance) the thermal stability of the CBM; and / or (iv) they may modulate (e.g., enhance) the solubility of the CBM; and / or (v) they may modulate (e.g., enhance) the in vivo half-life of a molecule
[0008] A "mutation" may include any alteration to a wild-type CBM molecule. For example, the term "mutation" may include, for example: (i) one or more amino acid substitutions (wherein one or more wild-type amino acids are replaced or changed with another (different) amino acid, the term "substitution" would include conservative amino acid substitutions); and / or (ii) one or more amino acid deletions (wherein one or more wild-type amino acid residues are removed); and / or (iii) one or more amino acid additions / insertions (wherein additional amino acid residues are added to the wild-type (or reference) primary sequence); and / or (iv) one or more amino acid / sequence inversions (typically where two or more consecutive amino acids in a primary sequence are inverted; and / or (v) one or more amino acid / sequence duplications (wherein an amino acid or a portion thereof (e.g., a stretch of 5-10 amino acids) of a primary amino acid sequence is repeated); As stated, a modified CBM according to the present disclosure may include one or more of the mutations described herein.
[0009] An exemplary wild-type CBM (in other words, a reference sequence from which useful modified CBMs can be derived) is the Streptococcus pneumoniae NanA sialidase, the amino acid sequence of which has been deposited under accession number P62575 and is reproduced below as SEQ ID NO:1 (1035 amino acids). SEQ ID NO:1 MSYFRNRDID IERNSMNRSV QERKCRYSIR KLSVGAVSMI VGAVVFGTSP VLAQEGASEQ PLANETQLSG ESSTLTDTEK SQPSSETELS GNKQEQERKD KQEEKIPRDY YARDLENVET VIEKEDVETN ASNGQRVDLS SELDKLKKLE NATVHMEFKP DAKAPAFYNL FSVSSATKKD EYFTMAVYNN TATLEGRGSD GKQFYNNYND APLKVKPGQW NSVTFTVEKP TAELPKGRVR LYVNGVLSRT SLRSGNFIKD MPDVTHVQIG ATKRANNTVW GSNLQIRNLT VYNRALTPEE VQKRSQLFKR SDLEKKLPEG AALTEKTDIF ESGRNGKPNK DGIKSYRIPA LLKTDKGTLI AGADERRLHS SDWGDIGMVI RRSEDNGKTW GDRVTITNLR DNPKASDPSI GSPVNIDMVL VQDPETKRIF SIYDMFPEGK GIFGMSSQKE EAYKKIDGKT YQILYREGEK GAYTIRENGT VYTPDGKATD YRVVVDPVKP AYSDKGDLYK GNQLLGNIYF TTNKTSPFRI AKDSYLWMSY SDDDGKTWSA PQDITPMVKA DWMKFLGVGP GTGIVLRNGP HKGRILIPVY TTNNVSHLNG SQSSRIIYSD DHGKTWHAGE AVNDNRQVDG QKIHSSTMNN RRAQNTESTV VQLNNGDVKL FMRGLTGDLQ VATSKDGGVT WEKDIKRYPQ VKDVYVQMSA IHTMHEGKEY IILSNAGGPK RENGMVHLAR VEENGELTWL KNHPIQKGEF AYNSLQELGN GEYGILYEHT EKGQNAYTLS FRKFNWDFLS KDLISPTEAK VKRTREMGKG VIGLEFDSEV LVNKAPTLQL ANGKTARFMT QYDTKTLLFT VDSEDMGQKV TGLAEGAIES MHNLPVSVAG TKLSNGMNGS EAAVHEVPEY TGPLGTSGEE PAPTVEKPEY TGPLGTSGEE PAPTVEKPEY TGPLGTAGEE AAPTVEKPEF TGGVNGTEPA VHEIAEYKGS DSLVTLTTKE DYTYKAPLAQ QALPETGNKE SDLLASLGLT AFFLGLFTLGKKREQ
[0010] The CBM region of SEQ ID NO:1 is amino acid residues 121-305, which sequence is designated SEQ ID NO:2 (the sequence is: VIEKEDVETN ASNGQRVDLS SELDKLKKLE NATVHMEFKP DAKAPAFYNL FSVSSATKKD EYFTMAVYNN TATLEGRGSD GKQFYNNYND APLKVKPGQW NSVTFTVEKP TAELPKGRVR LYVNGVLSRT SLRSGNFIKD MPDVTHVQIG ATKRANNTVW GSNLQIRNLT VYNRALTPEE VQKRS). Thus, the disclosure provides sialic acid binding molecules that include modified versions of SEQ ID NO:2 (and / or SEQ ID NO:1). The modified versions of SEQ ID NO:2 may include one or more mutated residues, for example, amino acid substitutions, additions / insertions, duplications, deletions and / or inversions made to the sequence of SEQ ID NO:2.
[0011] An exemplary Vibrio cholerae NanH sialidase amino acid sequence has been deposited under accession number A5F7A4 and is reproduced below as SEQ ID NO:3 (781 amino acids). SEQ ID NO:3 MRFKNVKKTA LMLAMFGMAT SSNAALFDYN ATGDTEFDSP AKQGWMQDNT NNGSGVLTNA DGMPAWLVQG IGGRAQWTYS LSTNQHAQAS SFGWRMTTEM KVLSGGMITN YYANGTQRVL PIISLDSSGN LVVEFEGQTG RTVLATGTAA TEYHKFELVF LPGSNPSASF YFDGKLIRDN IQPTASKQNM IVWGNGSSNT DGVAAYRDIK FEIQGDVIFR GPDRIPSIVA SSVTPGVVTA <h2 style=";text-align:left;direction:ltr">FAEKRVGGGD PGALSNTNDI ITRTSRDGGI TWDTELNLTE QINVSDEFDF SDPRPIYDPS<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> SNTVLVSYAR WPTDAAQNGD RIKPWMPNGI FYSVYDVASG NWQAPIDVTD QVKERSFQIA<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> GWGGSELYRR NTSLNSQQDW QSNAKIRIVD GAANQIQVAD GSRKYVVTLS IDESGGLVAN<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> LNGVSAPIIL QSEHAKVHSF HDYELQYSAL NHTTTLFVDG QQITTWAGEV SQENNIQFGN<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> ADAQIDGRLH VQKIVLTQQG HNLVEFDAFY LAQQTPEVEK DLEKLGWTKI KTGNTMSLYG<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> NASVNPGPGH GITLTRQQNI SGSQNGRLIY PAIVLDRFFL NVMSIYSDDG GSNWQTGSTL<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> PIPFRWKSSS ILETLEPSEA DMVELQNGDL LLTARLDFNQ IVNGVNYSPR QQFLSKDGGI<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> TWSLLEANNA NVFSNISTGT VDASITRFEQ SDGSHFLLFT NPQGNPAGTN GRQNLGLWFS<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> FDEGVTWKGP IQLVNGASAY SDIYQLDSEN AIVIVETDNS NMRILRMPIT LLKQKLTLSQ<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr"> N<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">
[0012] <h2 style=";text-align:left;direction:ltr"> The CBM region of SEQ ID NO:3 is amino acid residues 25-216, which sequence may be SEQ ID NO:4 (the sequence is: ALFDYNATGD TEFDSPAKQG WMQDNTNNGS GVLTNADGMP AWLVQGIGGR AQWTYSLSTN QHAQASSFGW RMTTEMKVLS GGMITNYYAN GTQRVLPIIS LDSSGNLVVE FEGQTGRTVL ATGTAATEYH KFELVFLPGS NPSASFYFDG KLIRDNIQPT ASKQNMIVWG NGSSNTDGVA AY). Thus, the disclosure provides sialic acid binding molecules that include modified versions of SEQ ID NO: 4 (and / or SEQ ID NO: 3). The modified versions of SEQ ID NO: 4 may include one or more mutated residues, for example, amino acid substitutions, additions / insertions, duplications, deletions and / or inversions made to the sequence of SEQ ID NO: 4.
[0013] As noted, the sialic acid binding molecules described herein may comprise one or more (e.g., two or more) modified CBMs. When a sialic acid binding molecule comprises two or more modified CBMs, the molecule may also be referred to as a multivalent CBM. A sialic acid binding molecule that is (or comprises) a multivalent CBM may be made as a construct that comprises multiple (two or more) modified CBMs linked by amino acid / peptide linkers. Each modified CBM may be linked to another by a peptide comprising, for example, 5, 10 or 15 amino acids. By way of example, any one or more of the following peptides may be used to link two or more CBMs to generate a sialic acid binding molecule that is a multivalent CBM: (i) 5 amino acid linker: ALXGS LQALG GGXSG GGALG GGSLG (ii) 10 amino acid linker: ALXGSGGGSG LQALGGGGSL (iii) 15 amino acid linker: ALXGSGGGSGGGGSG Here, "X" is any amino acid.
[0014] The sialic acid binding molecule for use may further comprise one or more oligomerization domains. As with the CBM elements of the sialic acid binding molecules of the present disclosure, the oligomerization domain may be derived from a wild-type oligomerization domain and may therefore comprise one or more mutations relative to the corresponding wild-type oligomerization domain sequence. Useful oligomerization domains exhibit the ability to self-associate to form multimeric structures, such as trimers. The modified oligomerization domain for use may comprise any molecule that has the same oligomerization properties. For the avoidance of doubt, the term "oligomerization domain" as used herein encompasses not only wild-type oligomerization domains, but also modified ones ("modified oligomerization domains" as disclosed herein).
[0015] For example, a sialic acid binding molecule according to the present disclosure may comprise one or more (e.g., two) CBMs (e.g., one, two or more modified CBMs described herein) attached, linked or fused to an oligomerization domain. The resulting sialic acid binding molecule is a (multimeric) CBM::oligomerization domain "fusion."
[0016] Suitable oligomerization domains include those obtainable from Pseudomonas aeruginosa pseudoaminidase. An exemplary Pseudomonas aeruginosa pseudoaminidase amino acid sequence is deposited under accession number Q9L6G4 (from strain PAO579) and is reproduced below as SEQ ID NO: 13 (438 amino acids). It should be recognized that similar, identical or otherwise useful oligomerization domains may be encompassed within the general term "oligomerization domain." SEQ ID NO:13 MNTYFDIPHR LVGKALYESY YDHFGQMDIL SDGSLYLIYR RATEHVGGSD GRVVFSKLEG GIWSAPTIVA QAGGQDFRDV AGGTMPSGRI VAASTVYETG EVKVYVSDDS GVTWVHKFTL ARGGADYNFA HGKSFQVGAR YVIPLYAATG VNYELKWLES SDGGETWGEG STIYSGNTPY NETSYLPVGD GVILAVARVG SGAGGALRQF ISLDDGGTWT DQGNVTAQNG DSTDILVAPS LSYIYSEGGT PHVVLLYTNR TTHFCYYRTI LLAKAVAGSS GWTERVPVYS APAASGYTSQ VVLGGRRILG NLFRETSSTT SGAYQFEVYL GGVPDFESDW FSVSSNSLYT LSHGLQRSPR RVVVEFARSS SPSTWNIVMP SYFNDGGHKG SGAQVEVGSL NIRLGTGAAV WGTGYFGGID NSATTRFATG YYRVRAWI
[0017] The oligomerization domain of SEQ ID NO: 13 is amino acid residues 333 to 438, which sequence may be SEQ ID NO: 14 (the sequence is: VPDFESDWFS VSSNSLYTLS HGLQRSPRRV VVEFARSSSP STWNIVMPSY FNDGGHKGSG AQVEVGSLNI RLGTGAAVWG TGYFGGIDNS ATTRFATGYY RVRAWI). As stated, the present invention may utilise modified oligomerisation domains. Modified oligomerisation domains may include oligomerisation domains that contain one or more mutations relative to a reference oligomerisation sequence. A "reference oligomerization sequence" may be any wild-type oligomerization domain sequence, including, for example, SEQ ID NOs: 13 and 14 above. Thus, the modified oligomerization domain may be derived from a given or particular wild-type oligomerization domain. The modified oligomerization domain sequence may comprise a wild-type oligomerization domain sequence containing one or more mutations.
[0018] The one or more mutations may be functional, i.e., they may individually (and / or independently) or collectively (e.g., synergistically) modulate (enhance or suppress / inhibit) one or more physiological, immunological, biological and / or pharmacological properties of the wild-type oligomerization domain (e.g., the wild-type oligomerization domain from which the modified oligomerization domain is derived). As noted above, the mutations may be: (i) may alter the immunogenicity (or antigenicity) of the oligomerization domain; and / or (ii) may improve potency (e.g., of a multimeric molecule comprising one or more modified CBMs); and / or (iii) they may modulate (e.g., enhance) the thermal stability of the oligomerization domain; and / or (iv) they may modulate (e.g., enhance) the solubility of the oligomerization domain; and / or (v) They may modulate (e.g., enhance) the in vivo half-life of the oligomerization domain. The term "mutation" in relation to a modified oligomerization domain is as defined above. In all cases, the mutations may modulate the immunological / antigenic properties of the CBM or oligomerization domain or a sialic acid binding molecule comprising same.
[0019] There are many factors that influence the immunogenicity of a protein. One important determinant is the presence of unique epitopes that can trigger T cell-dependent events leading to antibody production. T cells recognize short peptide fragments derived from the processing of protein antigens occurring within antigen-presenting cells (APCs). Some of these fragments will form complexes with human leukocyte antigen (HLA) / major histocompatibility complex (MHC) class II molecules and, if sufficiently stably bound, will be delivered to the surface of the APC and presented to T cells. Recognition of non-self peptides by T cell receptors triggers the ensuing immune response. Thus, to provide a less immunogenic CBM, the wild-type CBM and / or oligomerization domains may be analyzed to identify immunogenic / antigenic regions (i.e., regions or domains that may have or contain immunological epitopes). Immunogenicity (or antigenicity) is a property that can be assessed, for example, for a particular human or animal host; in other words, the CBM and / or oligomerization domains may be analyzed to determine which regions or domains may be immunogenic / antigenic in a particular (e.g., human) host. Immunogenicity (or antigenicity) may be assessed, for example, using in silico in screening techniques (e.g., screening for T cell epitopes, including (by way of example) ProPred in silico analysis), T cell proliferation assays, (including Proimmune human donor T cell proliferation assays) and other immunological techniques.Further information regarding methods for "deimmunizing" proteins can be derived from Jawa V, et al. ((2013) T-cell dependent immunogenicity of protein therapeutics: Preclinical assessment and mitigation. Clin Immunol. 149, 534-555) and Singh H, and Raghava GP ((2001) ProPred: prediction of HLA-DR binding sites. Bioinformatics. 17(12), 1236-7), the contents of which are incorporated by reference in their entirety.
[0020] Using these techniques, it was possible to identify immunogenic / antigenic regions of both the CBM and oligomerization domains. Figure 1 shows the complete analysis (ProPred prediction) of antigenic regions within the SpCBM sequence (Figure 1A) and the PaTD sequence (Figure 1B). The predicted binders are colored in blue and the first residue of each binding region is shown in red. The predicted antigenic peptides (green bars) and Proimmune (purple bars) are shown below the sequences.
[0021] For example, various regions between residues 127–300 in the SpCBM molecule (as shown in Figure 1A ) were identified as harboring immunogenic / antigenic domains, e.g., residues 127–135, 146–154, 154–166, 158–166, 143–151, 149–157, 167–176, 167–178, 182–196, 188–196, 185–193, 204–212, 213–221, 220–228, 239–246, 239–254, 241–249, 242–250, 243–251, 244–252, 245–253, 246–254, 247–255, 249–260, 249–261, 249–262, 249–263, 249–264, 249–265, 250–266, 251–267, 252–268, 253–269, 267–270, 267–271, 267–272, 267–273, 267–274, 267–275, 267–276, 267–278, 270–279, 271–279, 272–276, 273–277, 274–279, 275–278, 276–279, 277–279, 278–279, 280–28 Regions spanning 39–249, 239–247, 246–254, 243–251, 257–265, 267–275, 284–300, 284–299, 284–297, 286–284, 286–300, and 289–296 were identified as potentially immunogenic (some of which are predicted to bind a small number of alleles, while others are considered to be moderately or highly immunogenic).
[0022] More specifically, using the in silico and immunological (T cell proliferation) assays described above, the region spanning the following residues: 167 to 178 of SEQ ID NO: 1 (i.e., sequence: FYNLFSVSSATK) 167 to 181 of SEQ ID NO: 1 (i.e., the sequence: FYNLFSVSSATKKDE) 239 to 251 of SEQ ID NO: 1 (i.e., the sequence: VRLYVNGVLSRTS) 236 to 250 of SEQ ID NO: 1 (i.e., the sequence KGRVRLYVNGVLSRT) 245 to 254 of SEQ ID NO: 1 (i.e., sequence: GVLSRTSLRS) 286 to 294 of SEQ ID NO: 1 (i.e., the sequence IRNLTVYNR) was identified as immunogenic / antigenic. It should be noted that the region spanning residues 245-254 was identified as a site of significant immunogenicity.
[0023] The region between residues 336-424 within the PaTD oligomerization domain has been identified as having an immunogenic / antigenic domain. For example, the regions spanning residues 336-344, 340-348, 341-349, 348-356, 353-363, 355-363, 355-370, 362-370, 362-370 / 371, 375-383, 375-390, 400-407, 402-410, 397-405, 403-410 and 416-424 have been identified as potentially immunogenic (some of which are predicted to bind a small number of alleles, while others are considered moderately or highly immunogenic). As a non-limiting example, residues 338-352 of SEQ ID NO: 13 have been identified as having an immunogenic / antigenic domain.
[0024] More specifically, using the in silico and immunological (T cell proliferation) assays described above, the region spanning the following residues: 340 to 349 of SEQ ID NO: 13 (i.e., sequence: WFSVSSNSLY) 351 to 359 of SEQ ID NO: 13 (i.e., sequence: LSHGLQRSP) 398 to 406 of SEQ ID NO: 13 (i.e., the sequence: GSLNIRLGT) 392 to 406 of SEQ ID NO: 13 (i.e., the sequence: GAQVEVGSLNIRLGT) 338 to 352 of SEQ ID NO: 13 (i.e., the sequence: SDWFSVSSNSLYTLS) were identified as immunogenic / antigenic. It should be noted that the regions spanning residues 340-349, 351-359, and 398-406 were identified as sites of significant immunogenicity. Collectively, these regions (of both the CBM and oligomerization domains) will be referred to as the "immunogenic / antigenic" regions. Thus, modified CBMs and / or oligomerizations for use can be formed, for example, by mutating (e.g., substituting, removing, adding, inverting and / or overlapping) one or more amino acid residues (or amino acid sequences) within the above identified regions of immunogenicity / antigenicity.
[0025] Thus, a modified CBM or oligomerization domain according to the present disclosure may comprise an altered immunogenic (or antigenic) profile. In other words, when compared to a wild-type CBM or oligomerization domain, a modified CBM / oligomerization domain according to the present disclosure may be less immunogenic / antigenic (or may be differently immunogenic / antigenic) in a human or animal host. One skilled in the art will appreciate that mutations introduced into the primary amino acid sequence of a CBM or oligomerization domain can modulate immunogenicity by making certain epitopes more or less immunogenic.
[0026] Thus, in one aspect, the present invention provides a method of obtaining a CBM with an altered immunological profile, comprising determining which regions or domains of the CBM primary, secondary and / or tertiary amino acid sequence / structure are immunogenic and mutating one or more amino acid residues or sequences within one or more of the determined immunogenic / antigenic regions or domains. Furthermore, the present invention provides a modified CBM obtainable by a method for obtaining a CBM with a modified immunological profile (as described above).
[0027] Additionally, the disclosure provides a method of obtaining an oligomerization domain with an altered immunological profile, comprising determining which regions or domains of the oligomerization domain CBM primary, secondary and / or tertiary amino acid sequence / structure are immunogenic and mutating one or more amino acid residues or sequences within the one or more determined immunogenic / antigenic regions or domains. Furthermore, the present invention provides modified oligomerization domains obtainable by the method of obtaining an oligomerization domain with a modified immunological profile (as described above). The disclosure further provides a method for obtaining an engineered multimeric CBM, the method comprising: Obtaining at least one CBM having an altered immunological profile as described above, and optionally obtaining an oligomerization domain having an altered immunological profile as described above; and generating a multimeric CBM comprising at least one modified CBM.
[0028] The immunogenicity / antigenicity of the CBM / oligomerization domain may be subject to individual amino acid mutations. For example, specific amino acid residues may be replaced (substituted with another) or removed. To predict the effect of any given mutation, the modified sequence (containing at least one mutation relative to the reference sequence) may be provided, for example, to a program designed to identify immunogenic sequences (e.g., containing MHC binding regions within antigen sequences). Those skilled in the art will be familiar with suitable programs and systems, but ProPred is one example, the purpose of which is to predict MHC class II binding regions in antigen sequences using a quantitative matrix derived from published literature by Sturniolo et. al., 1999. This server assists in locating promiscuous binding regions. The user will aim to identify mutations that will affect the immunogenicity / antigenicity of the CBM / oligomerization domain, but at the same time will not affect the protein structure (which may be crucial for the sialic acid binding properties of the CBM and the oligomerization properties of the oligomerization domain). For example, the modified CBMs disclosed herein may maintain binding affinity for sialyllactose, for example, as assessed by surface plasmon resonance (SPR).
[0029] Based on the above, and using the SpCBM molecule as an example, one or more of the following residues may be mutated: Residues 167(F), 168(Y), 169(N), 170(L), 171(F), 172(S), 173(V), 174(S), 175(S), 176(A), 177(T ), 178(K), 179(K), 180(D), 181(E), 236(K), 237(G), 238(R), 239(V), 240(R), 241(L), 242(Y ), 243(V), 244(N), 245(G), 246(V), 247(L), 248(S), 249(R), 250(T), 251(S), 252(L), 253(R), 254(S), 286(I), 287(R), 288(N), 289(L), 290(T), 291(V), 292(Y), 293(N) and / or 294(R)
[0030] Based on the above, and using PaTD as an example, one or more of the following residues may be mutated: Residues 338(S), 339(D), 340(W), 341(F), 342(S), 343(V), 344(S), 345(S), 346(N), 3 47(S), 348(L), 349(Y), 350(T), 351(L), 352(S), 353(H), 354(G), 355(L), 356(Q ), 357(R), 358(S), 359(P), 392(G), 393(A), 394(Q), 395(V), 396(E), 397(V), 398(G), 399(S), 400(L), 401(N), 402(I), 403(R), 404(L), 405(G) and / or 406(T).
[0031] It should be noted that the term "mutation" includes the addition of further amino acids to any region ("immunogenic / antigenic region) that contains these residues. Furthermore, the term "mutation" may include duplication of any one or more amino acids and / or inversion of any sequence within these regions. For example, a short sequence of two or more (e.g., 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 (or more)) amino acids may be inverted (and / or duplicated). If the mutation is a substitution, the substituted amino acid may be any one of the other 19 naturally occurring or artificial or synthetic amino acids. Furthermore, the substituted amino acid may be a derivative or analogue of the wild-type amino acid at the relevant position.
[0032] As non-limiting examples, with respect to SpCBM, one or more of the following mutations may be made (although not all of these mutations may be directed to modulating the immunogenicity of the CBM), for example, one or more mutations (including mutations M156F and M185I) may be used to modulate thermostability. (i) M156F (ii) Y168W (referred to as "Im15") (iii) L170A (referred to as "Im16") (iv) L170T (referred to as "Im17") (v) V173G (referred to as "Im18") (vi) M185I (vii) V239A (referred to as "Im19") (viii) V239T (referred to as "Im20") (ix) V246G (referred to as "Im21") (x) I286A (called "Im22") (xi) Y292E (referred to as "Im23") Additionally, again by way of non-limiting example, one or more of the following mutations may be made to the PaTD molecule: (i) S342D (referred to as "Im24") (ii) S345D (referred to as "Im25") (iii) L348D (referred to as "Im26") (iv) R403K (referred to as "Im27")
[0033] For the avoidance of doubt, any of the CBM mutations listed as (i)-(xi) above, and any of the PaTD mutations listed as (i)-(iv) above, may be made individually and / or in combination with one or more of the other listed mutations. For example, mutations at two or more of residues 156, 170 and 185 or 239, 246, 286 and 292 or 156, 170, 185, 239, 246, 286 and 292 may be combined. Additionally or alternatively, mutations at residues 239 and 246 or 286 and 292 may be combined. Moreover, the mutations listed above are merely examples, and it will be appreciated that any mutation at the indicated positions that results in a CBM / oligomerization domain with the desired properties (e.g., reduced immunogenicity / antigenicity in a human host) should be included within the scope of the invention.
[0034] There are many techniques that allow a person skilled in the art to introduce one or more amino acid mutations into a CBM or oligomerization domain sequence. Any of these techniques may be used herein, including, for example, mutagenesis techniques, including (site-)directed mutagenesis, PCR mutagenesis, insertional mutagenesis, signature tagged mutagenesis, transposon mutagenesis and / or sequence saturation mutagenesis. Gene synthesis techniques can also be used to introduce any one or more mutations described herein. Prior to any mutagenesis procedure, the wild-type CBM and / or oligomerization domain nucleic acid sequences may be subjected to a codon optimization process in which codons are optimized for expression in an expression system, such as a bacterial (e.g., E. coli) expression system.
[0035] Useful sialic acid binding molecules may comprise monomeric modified CBMs (i.e., a single modified CBM) and others may be multimeric, i.e., molecules comprising two or more CBMs (e.g., two or more modified CBMs). In such cases, the sialic acid binding molecules may be referred to as "multimeric CBMs." Sialic acid binding molecules comprising multiple CBMs may comprise two or more modified CBMs, in which case some but not all CBMs within the sialic acid binding molecule are modified. In other words, sialic acid binding molecules comprising two or more CBMs may comprise a mixture of modified and unmodified CBMs. In one embodiment, the sialic acid binding molecule may comprise a hexameric CBM. A hexameric CBM comprises six CBM monomers. In most cases, the hexameric CBM comprises two fused CBMs, which are further linked to themselves by a fused oligomerization (trimerization) domain.
[0036] By way of example, the general structure of a useful hexameric CBM molecule can be represented as follows: [ka] The schematic (and general) structure above shows a sialic acid binding molecule that comprises three repeating units, each of which contains two CBMs (CBM1 and CBM2) and an oligomerization domain (in this case a trimerization domain: TD).
[0037] As described herein, one or both of the CBM moieties may be a modified CBM as described herein. Each repeat unit may be the same or different, in other words, each of the repeat units may contain two CBMs (modified or different) at the same time. The type of CBM and / or the level or degree of modification may vary. As a non-limiting example, one repeat unit may contain two CBMs with a wild-type sequence. Another one may contain two different CBMs, one with a wild-type sequence and one with a modified sequence (containing one or more mutations as described herein). A third repeat unit may contain two modified CBMs (containing one or more mutations as described herein). Those skilled in the art will understand that other combinations of CBM types and / or sequences (wild-type vs. mutant sequences) may be made and tested.
[0038] As non-limiting examples, the following represent individual units (referred to as "HEX" units) that may be used to create hexameric sialic acid binding molecules. In each case, the HEX units contain two modified CBMs (designated CBM1 and CBM2), with the specific mutations introduced into each CBM specified in brackets. It should be noted that the "----" symbols indicate an amino acid linker (connecting one CBM to another, or a CBM to an oligomerization domain). Thus, a hexameric sialic acid binding molecule may be composed of several (e.g., three) HEX units. In each case, an oligomerization domain (designated "TD") links the units together as a trimer. Any given hexamer may contain identical copies of the units described above (and below) under the headings HEX1, HEX2, HEX3, HEX4, HEX5, HEX6 and HEX17, although one of skill in the art will appreciate that further options are available. For example, a HEX unit may be composed of two CBMs, each having a different mutation (one or more of the mutations selected from the options detailed herein). (i) HEX1 CBM1 (L170T V239A V246G I286A Y292E)-----CBM2 (L170T V239A V246G I286A Y292E)-----TD (S342D L348D R403K) (ii) HEX2 CBM1 (V239A V246G I286A Y292E)----CBM2 (V239A V246G I286A Y292E)----TD (S342D R403K) (iii) HEX3 CBM1 (V239A V246G I286A)-----CBM2 (V239A V246G I286A)-----TD (S342D R403K) (iv) HEX4 CBM1 (V239A V246G)-----CBM2 (V239A V246G)-----TD (S342D) (v) HEX5 CBM1 (V239A V246G)-----CBM2 (V239A V246G)-----TD (R403K) (vi) HEX6 CBM1 (V239A V246G)-----CBM2 (V239A V246G)-----TD (S342D R403K) (vii) HEX17 CBM1 (V239A V246G A162P)-----CBM2 (V239A V246G A162P)-----TD (S342D R403K)
[0039] It should be noted that HEX6 and HEX17 are identical except for the additional A162P mutation. This proline mutation (substitution of wild type alanine at residue 162) was shown to improve thermal stability (single CBM Tm by only 3-4°C). Further information on the use of proline mutations can be derived from Fu 2009, 'Increasing protein stability by improving beta-turns' (DOI 10.1002 / prot.22509), which describes the general approach. The proline mutation does not affect (increase or decrease) the predicted immunogenicity of the CBM molecule and is not located near other mutations, the N- or C-terminus or the ligand binding site. Rather unexpectedly, beyond a moderate improvement in thermal stability, it was confirmed that the A162P mutation leads to a hexameric CBM (i.e., HEX17) that shows a significant improvement in in vivo experiments, especially compared to those same experiments performed with HEX6. For example, modified molecules (especially those containing 3×HEX17 units) exhibit modulation of pro-inflammatory cytokines, including, for example, IL-8. Indeed, the modulatory effect (especially the inhibitory effect) on the production of IL-8 by molecules containing 3×HEX17 units was improved over the other modified molecules tested.
[0040] The amino acid sequences of the HEX6 and HEX17 molecules, compared to the Sp2CBMTD (aka "SpOrig") amino acid sequence, are as follows: SpOrig GAMVIEKEDVETNASNGQRVDLSSELDKLKKLENATVHMEFKPDAKAPAFYNLFSVSSAT HEX6 GAMVIEKEDVETNASNGQRVDLSSELDKLKKLENATVHMEFKPDAKAPAFYNLFSVSSAT HEX17 GAMVIEKEDVETNASNGQRVDLSSELDKLKKLENATVHMEFKPDPKAPAFYNLFSVSSAT SpOrig KKDEYFTMAVYNNTATLEGRGSDGKQFYNNYNDAPLKVKPGQWNSVTFTVEKPTAELPKG HEX6 KKKDEYFTMAVYNNTATLEGRGSDGKQFYNNYNDAPLKVKPGQWNSVTFTVEKPTAELPKG HEX17 KKKDEYFTMAVYNNTATLEGRGSDGKQFYNNYNDAPLKVKPGQWNSVTFTVEKPTAELPKG SpOrig RVRLYVNGVLSRTSLRSGNFIKDMPDVTHVQIGATKRANNTVWGSNLQIRNLTVYNRALT HEX6 RARLYVNGGLSRTSLRSGNFIKDMPDVTHVQIGATKRANNTVWGSNLQIRNLTVYNRALT HEX17 RARLYVNGGLSRTSLRSGNFIKDMPDVTHVQIGATKRANNTVWGSNLQIRNLTVYNRALT Question: PEEVQKRSGGGSGVIEKEDVETNASNGQRVDLSSELDKLKKLENATVHMEFKPDAKAPAF HEX6 PEEVQKRSGGGSGVIEKEDVETNASNGQRVDLSSELDKLKKLENATVHMEFKPDAKAPAF HEX17 PEEVQKRSGGGSGVIEKEDVETNASNGQRVDLSSELDKLKKLENATVHMEFKPDPKAPAF SpOrig YNLFSVSSATKKDEYFTMAVYNNTATLEGRGSDGKQFYNNYNDAPLKVKPGQWNSVTFTV HEX6 YNLFSVSSATKKDEYFTMAVYNNTATLEGRGSDGKQFYNNYNDAPLKVKPGQWNSVTFTV HEX17 YNLFSVSSATKKDEYFTMAVYNNTATLEGRGSDGKQFYNNYNDAPLKVKPGQWNSVTFTV SpOrig EKPTAELPKGRVRLYVNGVLSRTSLRSGNFIKDMPDVTHVQIGATKRANNTTVWGSNLQIR HEX6 EKPTAELPKGRARLYVNGGLSRTSLRSGNFIKDMPDVTHVQIGATKRANNTVWGSNLQIR HEX17 EKPTAELPKGRARLYVNGGLSRTSLRSGNFIKDMPDVTHVQIGATKRANNTVWGSNLQIR SpOrig NLTVYNRALTPEEVQKRSGGALGVPDFESDWFSVSSNSLYTLSHGLQRSPRRVVVEFARS HEX6 NLTVYNRALTPEEVQKRSGGSLGVPDFESDWFDVSSNSLYTLSHGLQRSPRRVVVEFARS HEX17 NLTVYNRALTPEEVQKRSGGSLGVPDFESDWFDVSSNSLYTLSHGLQRSPRRVVVEFARS SpOrig SSPSTWNIVMPSYFNDGGHKGSGAQVEVGSLNIRLGTGAAVWGTGYFGGIDNSATTRFAT HEX6 SSPSTWNIVMPSYFNDGGHKGSGAQVEVGSLNIKLGTGAAVWGTGYFGGIDNSATTRFAT HEX17 SSPSTWNIVMPSYFNDGGHKGSGAQVEVGSLNIKLGTGAAVWGTGYFGGIDNSATTRFAT SporiGYYRVRAWI HEX6 GYYRVRAWI HEX17 GYYRVRAWI
[0041] While not wishing to be bound to any particular use or application, the molecules of the present disclosure include: (i) for the treatment and / or prevention of disease in a subject in need thereof; (ii) in modulating the immune response (in a human or animal subject); (iii) in the regulation of cell growth, proliferation and / or differentiation (iv) as an adjuvant; and / or (vi) In the manufacture of medicines In some cases it may be useful.
[0042] Again without wishing to be bound by any particular use, the molecules of the present disclosure may be used (as drugs) in the treatment and / or prevention of various diseases and / or conditions, particularly diseases or conditions caused or brought about by pathogens, especially pathogens capable of binding to cell surface sialic acid-containing receptors. The present disclosure may also provide methods useful for the treatment of subjects, especially human subjects, suffering from or at risk of coming into contact with diseases and / or conditions caused or brought about by pathogens, especially pathogens capable of binding to cell surface sialic acid-containing receptors. For example, the term "pathogen" may encompass any pathogen capable of binding to, recognizing, or otherwise associating with cell surface carbohydrates, especially pathogens that have evolved to exploit or take advantage of the presence of cell surface (sialic acid) carbohydrates as a means of binding / attaching to and / or entering cells. Thus, the term "pathogen" may include microbial pathogens, including respiratory pathogens such as viruses belonging to the Orthomyxoviridae or Paramyxoviridae families, e.g., influenza and human parainfluenza, as well as bacteria belonging to the genus Streptococcus (e.g., Streptococcus pneumoniae) and / or Haemophilus influenzae, Pseudomonas aeruginosa, all of which can bind to carbohydrates on the surface of mammalian cells. Those skilled in the art will appreciate that the mammalian cells most frequently colonized / invaded by pathogens of the types described herein are epithelial cells, particularly epithelial cells lining mucosal tracts (e.g., respiratory epithelial cells). For a complete disclosure of how sialic acid-binding molecules can be used to treat or prevent disease, see PCT / GB2009 / 002189, the entire contents of which are incorporated herein by reference.
[0043] With respect to modulating immune responses (in human or animal subjects), various sialic acid binding molecules (molecules comprising one or more modified CBMs) described herein have immunomodulatory properties. For example (without wishing to be bound by theory), the sialic acid binding molecules of the present disclosure modulate the host immune response, stimulate the immune system, modulate (e.g., increase or decrease) the expression, function and / or activity of immune system processes, pathways and / or any components thereof. The term "stimulating", when used in reference to immune responses, may also encompass the phenomenon of increasing the readiness and / or responsiveness of the immune system to an immunogen, antigen, pathogen, disease or infection. Without wishing to be bound by theory, in addition to any immunomodulatory properties associated with the sialic acid binding molecules disclosed herein, a subject administered or contacted with a sialic acid binding molecule of the present disclosure may be better able to deal with the onset of infection / disease. For a complete disclosure of the immunomodulatory activity of sialic acid binding molecules, see PCT / GB2015 / 050161, the contents of which are incorporated herein by reference in their entirety.
[0044] It has further been shown that the sialic acid binding molecules of the present disclosure (which may include one or more modified CBMs) may be used to modulate aspects of cell growth and / or cell activity. The terms "growth" and "activity", when used in reference to a cell, may include processes and / or phenomena associated with one or more of cell proliferation, cell viability, cell migration, cell metabolism, cell differentiation and / or cell morphology / phenotype. The terms "growth" and / or "activity" may further include the response of a cell to certain exogenous and / or endogenous factors or stimuli, including, for example, responses to certain compounds of the immune system, cytokines, chemokines and one or more environmental factors (light, temperature, pressure, mechanical stress and the like). Thus, the sialic acid binding molecules disclosed herein may be used to modulate (inhibit, reduce or increase) the level of cell responsiveness. Thus, any molecule of the present disclosure may be used in the treatment or prevention of diseases and / or conditions caused, brought about and / or characterized by aberrant cell growth and / or activity, or in the manufacture of a medicament for treating or preventing the same.
[0045] Without wishing to be bound by any particular medical application, it should be noted that diseases caused, brought about or characterized by abnormal cell growth and / or activity may include, for example, cell proliferation and / or differentiation disorders, including those referred to or classified as benign or malignant conditions. For example, the term "cell proliferation and / or differentiation disorders" may include diseases and / or conditions collectively referred to as "cancer." The term "cancer" may include, but is not limited to, cancers referred to as forms of breast cancer, bone cancer, brain cancer (glioma), pancreatic cancer, lung cancer, prostate cancer, skin cancer, ovarian cancer, cervical cancer, head and neck cancer and intestinal / colon cancer. The term "cancer" may also include diseases and / or conditions collectively referred to as "leukemias" (both chronic and acute) and any cancer affecting mucosa / mucosa-related surfaces or tissues.
[0046] Thus, the sialic acid binding molecules described herein, which may include one or more modified CBMs, may find use (i.e., may be for use) in the treatment and / or prevention of cancer. The sialic acid binding molecules of the present disclosure may further be used in the manufacture of a medicament for the treatment and / or prevention of cancer. For a complete disclosure of how sialic acid binding molecules can be used to regulate cell growth and / or cell activity, see PCT / GB2017 / 052808, the entire contents of which are incorporated herein by reference.
[0047] Any of the disclosed sialic acid-binding molecules (including one or more modified CBMs) may be used as adjuvants or may be used in combination with one or more antigens to increase, modulate or improve the host immune response to one or more antigens. It should be noted that the sialic acid-binding molecule-based adjuvants disclosed herein may be combined with any type of antigen, but the adjuvants that are the subject of the present disclosure may be particularly useful as mucosal adjuvants, i.e., adjuvants for use with antigens administered to the mucosa. For a complete disclosure of how sialic acid-binding molecules can be used as adjuvants, see PCT / GB2017 / 052805, the entire contents of which are incorporated herein by reference.
[0048] It has also been shown that the sialic acid binding molecules of the present disclosure (which may include one or more modified CBMs) may find utility in the treatment and / or prevention of sepsis. The term "sepsis" is used for several diseases, conditions and / or syndromes that may have an infectious (e.g., viral, bacterial and / or fungal) etiology. For example, the term "sepsis" may include disease states, conditions or syndromes referred to as SIRS (systemic inflammatory response syndrome: see Singer et al, 2016: JAMA "The third International consensus definitions for sepsis and septic shock), sepsis (often defined as "SIRS in response to an infectious process"), severe sepsis (sepsis with sepsis-induced organ failure or tissue hypoperfusion (which may itself manifest as low blood pressure, elevated lactate or decreased urine output)) and septic shock (severe sepsis plus, for example, persistent hypotension despite administration of intravenous fluids). The term "sepsis" is most often used for diseases, conditions and / or syndromes that result from "bacterial sepsis". Bacterial sepsis may result from the presence of bacteria in the blood and may also be referred to as "bacteremia" or "septicaemia." The term "sepsis" may also encompass diseases and / or conditions caused or resulting from the presence of bacterial components, such as LPS, toxins and / or membrane fragments, in the blood. Components of this type may also result from primary infections present in other tissues and / or organs, for example infections present in the lungs, brain, skin, urinary tract, pelvis and / or abdomen. For a complete disclosure of how sialic acid binding molecules can be used to treat and / or prevent sepsis, see PCT / GB2017 / 052800, the entire contents of which are incorporated herein by reference.
[0049] The modified CBMs described herein and any molecules that contain the same may be bound, linked or associated with other elements to target or deliver the element to some tissues or cells. This type of molecule may also be known as a "therapeutic warhead" or "conjugate." Without wishing to be bound by theory, the presence of ligands for the various modified CBMs that may be included within the molecules of the present disclosure at certain cell receptors and membrane-bound molecules may allow the various molecules described herein to be utilized as a means to deliver bound heterologous molecules (which are separate and distinct from the modified CBM or molecules that contain the same) to said cells or tissues that contain said cells. Such bound molecules may be useful, for example, in the treatment of various diseases, including cancer, in which the bound molecules described herein (molecules that exhibit affinity for carbohydrates expressed on the surface of cells) may be used to target therapeutic and / or cytotoxic moieties thereto. By way of example, a molecule described herein (including any modified CBM or molecule comprising the same) may be conjugated to one or more (e.g., two, three, four or more) moieties, e.g., therapeutic and / or cytotoxic. Useful molecules may comprise a modified CBM of the present disclosure conjugated (linked, attached, or otherwise associated) with a heterologous moiety. The heterologous moiety may include a therapeutic and / or cytotoxic moiety that may be attached to some portion of the modified CBM molecule. For example, a heterologous moiety may be attached to one or both ends of the modified CBM molecule. A heterologous moiety may additionally or alternatively be attached (or even fused) to an internal portion of the modified CBM molecule. It will be appreciated that although a heterologous moiety is attached to the modified CBM molecule, the molecule (and its attachment) should not (substantially) interfere with, eliminate or reduce the carbohydrate (sialic acid) binding properties of the modified CBM molecule.
[0050] As specified, the heterologous moiety may be a drug useful for treating a disease affecting cells or tissues expressing a receptor that includes a ligand for any one of the modified CBMs (or molecules that include the same) described herein. For example, the drug may be a chemotherapeutic drug for use in treating cancer and the like. The heterologous moiety may be a cytotoxic moiety that can kill cells or induce apoptosis of cells. The heterologous moiety may include a molecule that can recruit specific cells to or within a specific tissue. For example, the heterologous moiety may be a T cell receptor (TCR) that can be used as a means to recruit, for example, T cells to tumor or cancer tissue. The present disclosure can provide compositions for use in the various uses, agents and methods described herein. Thus, any modified CBM (or any molecule that includes a modified CBM) described herein can be formulated for use. For convenience, with respect to the sections below describing compositions, formulations and the like, it should be noted that both molecules comprising the modified CBMs described herein, molecules comprising the same and any composites comprising the same (e.g. modified CBM::drug composites / fusions) will be encompassed by the general term "molecule comprising a modified CBM."
[0051] Molecules comprising the modified CBM may be formulated for use as therapeutic or pharmaceutical compositions. Various compositions may include one or more of the molecules described herein, and any given treatment may require the administration (together, simultaneously, or separately) of one or more of these compositions. It should be noted that compositions according to the present disclosure may further include one or more other therapeutic moieties, such as molecules, small molecules, antibodies, oligonucleotides, and the like, useful for the treatment of one or more diseases and / or conditions. Additionally or alternatively, the modified CBM may be administered together with one or more other (different) therapeutic elements, where the one or more other (different) therapeutic elements may be used for the treatment of the same or different diseases. The term "administered together" encompasses administration of the modified CBM before, after, and / or simultaneously with administration of one or more other therapeutic elements. The molecules described herein may be formulated for enteral (including oral), parenteral and / or topical administration, and one of skill in the art will appreciate that the exact formulation may vary depending on the route of administration.
[0052] Pharmaceutical compositions according to the invention contain substances commonly used in medicines and may be conventionally prepared, for example, as described in Remington's The Sciences and Practice of Pharmacy, 22nd Edition (Pharmaceutical Press 2012) and / or Handbook of Pharmaceutical Excipients, 7th edition (compiled by Rowe et al, Pharmaceutical Press, 2012), the entire contents of all of which literature and references are incorporated by reference.
[0053] Therapeutic or pharmaceutical compositions of the present disclosure (compositions comprising molecules comprising modified CBMs and for use in any of the agents or methods described herein) may be formulated with one or more pharma- ceutically acceptable excipients, carriers, adjuvants, and buffers. The compositions may be administered, for example, orally (including mucosally), parenterally, enterally, intramuscularly, subcutaneously, intravenously, or via any other route useful for achieving the desired effect (e.g., modulation of cell growth / activity, treatment or prevention of diseases / conditions and / or cancers associated with the same, and / or modulation of tumor growth). As noted, the exact composition formulation may vary depending on the route of administration selected.
[0054] Therapeutic or pharmaceutical formulations containing a molecule comprising a modified CBM and for administration to a subject may be coated, encapsulated or encased in a material that protects the molecule from the action of enzymes, acids and other natural compounds / conditions (including, e.g., compounds (including antibodies), cells and processes of the immune system) that may inactivate or denature the compound and / or its carbohydrate-binding properties.
[0055] Among the various standard conventional excipients that may be available for use in compositions containing the molecules described herein are pharma- ceutically acceptable organic or inorganic carrier substances suitable for parenteral, enteral, oral (including mucosal) and other routes of administration that do not deleteriously react with the molecules, including the modified CBM. When the molecule comprising the modified CBM is formulated for parenteral administration, the composition may be sterile. The compositions may comprise oil-based or aqueous solutions, suspensions and / or emulsions. In other embodiments, the composition may be in the form of an implant, such as, for example, a film (dissolvable or biodegradable), a pessary or an implant (including suppositories). Pharmaceutical preparations containing the molecules described herein may be mixed with stabilizers, wetting agents, emulsifiers, salts (for use in affecting osmotic pressure), buffers, and / or other substances which do not deleteriously react with the active compounds. One or more molecules described herein may be formulated and administered orally. As noted, oral administration would include mucosal administration, which itself would include intranasal administration and / or administration by inhalation.
[0056] Compositions for use may include solid dosage forms suitable for oral administration. These may include, for example, capsules, tablets, pills, powders, and granules. In any given solid dosage form, the molecule comprising the modified CBM (or any molecule or compound comprising the same) may be mixed with at least one inert pharma- ceutically acceptable excipient. Examples of suitable excipients may include, for example, fillers or bulking agents, water-retaining agents, wetting agents, binders, disintegrants, solution retarders, absorption enhancers, adsorbents, lubricants, or mixtures thereof, as would be known to one skilled in the art. Tablets, pills, or capsules may further include a buffering agent. Solid dosage forms such as tablets, dragees, capsules, pills, and / or granules may also be prepared with coatings and shells, such as coatings that protect against the gastrointestinal environment and / or stomach acid. Solid dosage forms may contain an opacifying agent and may be formulated to ensure delayed release of the active agent (in this case a molecule comprising a modified CBM or a composite comprising the same) in or to a certain part of the intestinal tract.
[0057] Solid compositions for oral administration may be formulated into unit dosage forms, with each dosage containing an appropriate dose of the molecule comprising a modified CBM (or a compound comprising the same). The exact amount of the molecule comprising a modified CBM (or a compound comprising the same) contained within any given solid dosage form will vary depending on the intended use. The solid composition may comprise a "unit dose", which contains an amount of the molecule comprising a modified CBM (or a compound comprising the same) calculated to produce a desired effect (e.g., modulation of cell growth and / or activity) over the treatment period. Liquid dosage forms for oral administration (as specified) can include emulsions, solutions, suspensions, syrups, and elixirs. In addition to the compound or composition, liquid dosage forms can contain inert diluents, such as water or other solvents, solubilizing agents, and emulsifying agents commonly used in the art.
[0058] Any of the molecules of the present disclosure may be used in any suitable amount. As specified, the molecules may be formulated for oral, mucosal or parenteral administration, and therefore the exact formulation may depend on the intended route of administration and / or the physiological and / or other attributes of the subject. The amount of the molecule comprising the modified CBM present in any given dose may range from 0.1 μg to 1000 μg. For example, an amount of about 0.1 μg, 0.2 μg, 0.3 μg, 0.4 μg, 0.5 μg, 1 μg, 10 μg, 20 μg, 25 μg, 50 μg, 100 μg, 200 μg, 300 μg, 400 μg, 500 μg, 600 μg, 700 μg, 800 μg or 900 μg. Larger amounts of modified CBM (or molecules containing the same) may be used, for example amounts ranging from 1 mg to 10 mg, for example about 1 mg, 2 mg, 3 mg, 4 μg, 5 mg, 6 mg, 7 mg, 8 mg or 9 mg. A selected amount of modified CBM molecule may be formulated in a specific volume of a pharma- ceutically acceptable excipient, diluent and / or buffer. The volume of the excipient, diluent or buffer may be about 10 μl to 5 ml. For example, the required amount of CBM32 / 47 / 67 / 70 molecule may be combined (or formulated) with about 15 μl, 20 μl, 25 μl, 30 μl, 35 μl, 40 μl, 45 μl, 50 μl, 55 μl, 60 μl, 65 μl, 70 μl, 75 μl, 80 μl, 85 μl, 90 μl, 95 μl, 100 μl, 200 μl, 250 μl, 300 μl, 400 μl, 500 μl, 600 μl, 700 μl, 800 μl, 900 μl, 1 ml, 2 ml, 3 ml or 4 ml.For example, doses of concentrations from about 0.1 μg / ml to 10 mg / ml may be used, including doses of 5 μg / ml, 10 μg / ml, 20 μg / ml, 25 μg / ml, 50 μg / ml, 100 μg / ml, 200 μg / ml, 300 μg / ml, 500 μg / ml, 600 μg / ml, 700 μg / ml, 800 μg / ml or 900 μg / ml, 950 μg / ml, 1 mg / ml, 1.5 mg / ml, 2 mg / ml, 2.5 mg / ml, 3 mg / ml, 3.5 mg / ml, 4 mg / ml, 4.5 mg / ml, 5 mg / ml, 5.5 mg / ml, 6 mg / ml, 6.5 mg / ml, 7 mg / ml, 7.5 mg / ml, 8 mg / ml, 8.5 mg / ml, 9 mg / ml or 9.5 mg / ml.
[0059] In use, the dose of modified CBM molecule administered as part of the treatment and / or prevention of a disease (e.g., a cell proliferation and / or differentiation disorder or cancer) may be administered multiple times over a period of days, weeks, months or years. For example, a dose of modified CBM molecule may be administered again about (+ / - 1 or 2 days) 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 21, 28 and / or 35 days after the initial (or first) administration. Multiple repeat doses may be given at regular intervals, for example every 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27 or 28 days after the preceding dose. On any given day, a particular dose of the modified CBM molecule may be administered one, two, three or more times, each time being administered (by whatever route is deemed best) to affect a suitable treatment or provide prophylaxis against a particular disease or condition. The invention will now be described in detail with reference to the following figures, which show: [Brief description of the drawings]
[0060] [Figure 1A]Figure 1. ProPred prediction of antigenic peptides. A. SpCBM sequence. B. PaTD sequence. Predicted binders are colored blue, with the first residue of each binding region shown in red. Antigenic peptides predicted by Nordic Biopharma (green bars) and Proimmune (purple bars) are shown below the sequences. [Figure 1B] Figure 1. ProPred prediction of antigenic peptides. A. SpCBM sequence. B. PaTD sequence. Predicted binders are colored blue, with the first residue of each binding region shown in red. Antigenic peptides predicted by Nordic Biopharma (green bars) and Proimmune (purple bars) are shown below the sequences. [Diagram 2] Expression study of wild type and mutant domains. Lane 1, M12 standard; lane 2, WTspCBM; lanes 3-11, Im15-Im23; lanes 12-15, Im24-Im27; lane 16, WT PaTD. A) Whole cell extract, B) Soluble extract. [Diagram 3] FIG. 1 shows the positions of peptides 167-181 in the SpCBM structure. [Figure 4] FIG. 1 shows expression and Ni-NTA pull-down of variants Im28 to Im34. [Diagram 5] Figure 1. Sites of HEX17 mutations on the hexameric structure. The quaternary structure of HEX17 was modeled by combining the crystal structures of the individual SpCBM (pdb code 4c1x) and PaTD (pdb code 2w38) to create a hexamer (i.e., 6 copies of SpCBM and 3 copies of PaTD per molecule). The position of the bound ligand (α2,3-sialyllactose) is shown in sticks (orange). The positions of the mutations are also indicated as follows: blue, site of the A162P mutation; light blue, sites of the other two CBM mutations; magenta, sites of the TD mutations. [Figure 6]1 is a graph showing IL-8 stimulation. A549 cells were stimulated by the addition of 10 μg of biologics (Sp2CBMTD (also known as SpOrig), HEX6, or HEX17). Cell supernatants were harvested at 24 h or 48 h, and IL-8 content was determined by ELISA. Statistical significance between control and treated cells was determined using one-way ANOVA with Tukey's multiple comparison test. [Figure 7A] Figure 1 shows multiplex analysis of inflammatory mediators. A549 cells were stimulated by addition of 10 μg of biologics (Sp2CBMTD (also known as SpOrig), HEX6 or HEX17). Cell supernatants were harvested at 6 h, 24 h or 48 h and inflammatory mediators were analyzed using human Cytokine 12-plex assay. Statistical significance between control and / or WT hexamer and hexamer variants was determined using one-way ANOVA (Tukey multiple comparison test). [Figure 7B] Figure 1 shows multiplex analysis of inflammatory mediators. A549 cells were stimulated by addition of 10 μg of biologics (Sp2CBMTD (also known as SpOrig), HEX6 or HEX17). Cell supernatants were harvested at 6 h, 24 h or 48 h and inflammatory mediators were analyzed using human Cytokine 12-plex assay. Statistical significance between control and / or WT hexamer and hexamer variants was determined using one-way ANOVA (Tukey multiple comparison test). [Figure 7C] Figure 1 shows multiplex analysis of inflammatory mediators. A549 cells were stimulated by addition of 10 μg of biologics (Sp2CBMTD (also known as SpOrig), HEX6 or HEX17). Cell supernatants were harvested at 6 h, 24 h or 48 h and inflammatory mediators were analyzed using human Cytokine 12-plex assay. Statistical significance between control and / or WT hexamer and hexamer variants was determined using one-way ANOVA (Tukey multiple comparison test). [Figure 7D]Figure 1 shows multiplex analysis of inflammatory mediators. A549 cells were stimulated by addition of 10 μg of biologics (Sp2CBMTD (also known as SpOrig), HEX6 or HEX17). Cell supernatants were harvested at 6 h, 24 h or 48 h and inflammatory mediators were analyzed using human Cytokine 12-plex assay. Statistical significance between control and / or WT hexamer and hexamer variants was determined using one-way ANOVA (Tukey multiple comparison test). [Figure 7E] Figure 1 shows multiplex analysis of inflammatory mediators. A549 cells were stimulated by addition of 10 μg of biologics (Sp2CBMTD (also known as SpOrig), HEX6 or HEX17). Cell supernatants were harvested at 6 h, 24 h or 48 h and inflammatory mediators were analyzed using human Cytokine 12-plex assay. Statistical significance between control and / or WT hexamer and hexamer variants was determined using one-way ANOVA (Tukey multiple comparison test). [Figure 7F] Figure 1 shows multiplex analysis of inflammatory mediators. A549 cells were stimulated by addition of 10 μg of biologics (Sp2CBMTD (also known as SpOrig), HEX6 or HEX17). Cell supernatants were harvested at 6 h, 24 h or 48 h and inflammatory mediators were analyzed using human Cytokine 12-plex assay. Statistical significance between control and / or WT hexamer and hexamer variants was determined using one-way ANOVA (Tukey multiple comparison test). [Figure 8] Graph showing the survival percentage of CBM-treated and untreated mice when lethally challenged with influenza strain PR8. CBM2, CBM3 and CBM4 represent HEX17, HEX6 and WT(SpOrig), respectively. Animals treated with a single dose of CBM received 100 μg of CBM 1 day prior to lethal challenge with PR8, and animals treated repeatedly received 2×0.1 μg of CBM 3 and 1 day prior to PR8 challenge. [Figure 9]Figure 1 shows the clinical scores of CBM-treated and untreated mice during PR8 infection. CBM2, CBM3 and CBM4 represent HEX17, HEX6 and WT(SpOrig), respectively. The ascending clinical scores of 1 to 5 indicate asymptomatic (1) to coma and death (5), respectively. [Figure 10] Graph showing the percentage of weight loss in CBM-treated and untreated mice during PR8 infection. CBM2, CBM3 and CBM4 represent HEX17, HEX6 and WT(SpOrig), respectively. [Figure 11A] Graph showing anti-mCBM antibody analysis of lung homogenates and serum tissues from the PR8 challenge mouse study on day 21. Statistical significance between WT hexamer and hexamer variants was determined using one-way ANOVA (Tukey's multiple comparison test). [Figure 11B] Graph showing anti-mCBM antibody analysis of lung homogenates and serum tissues from the PR8 challenge mouse study on day 21. Statistical significance between WT hexamer and hexamer variants was determined using one-way ANOVA (Tukey's multiple comparison test). [Figure 11C] Graph showing anti-mCBM antibody analysis of lung homogenates and serum tissues from the PR8 challenge mouse study on day 21. Statistical significance between WT hexamer and hexamer variants was determined using one-way ANOVA (Tukey's multiple comparison test). [Figure 11D] Graph showing anti-mCBM antibody analysis of lung homogenates and serum tissues from the PR8 challenge mouse study on day 21. Statistical significance between WT hexamer and hexamer variants was determined using one-way ANOVA (Tukey's multiple comparison test). [Figure 12a-1] 1 is a graph showing anti-CBM antibody levels in BAL mouse samples on day 35. [Figure 12a-2] 1 is a graph showing anti-CBM antibody levels in BAL mouse samples on day 35. [Figure 12a-3] 1 is a graph showing anti-CBM antibody levels in BAL mouse samples on day 35. [Figure 12a-4] 1 is a graph showing anti-CBM antibody levels in BAL mouse samples on day 35. [Figure 12b-1] 1 is a graph showing anti-CBM antibody levels in serum mouse samples on day 35. [Figure 12b-2] 1 is a graph showing anti-CBM antibody levels in serum mouse samples on day 35. [Figure 12b-3] 1 is a graph showing anti-CBM antibody levels in serum mouse samples on day 35. [Figure 12b-4] 1 is a graph showing anti-CBM antibody levels in serum mouse samples on day 35. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0061] Methods and Results Sp2CBMTD: prediction of immunogenic regions Nordic Biopharma in silico screening In silico T cell epitope screening identified four prominent and two borderline immunogenic populations. Notable: Domain Residue Range Sequence SpCBM 245~254 GVLSRTSLRS PaTD 340~349 WFSVSSNSLY PaTD 351~359 LSHGLQRSP PatD 398~406 GSLNIRLGT boundary: Domain Residue Range Sequence SpCBM 167~178 FYNLFSVSSATK SpCBM 239~251 VRLYVNGVLSRTS
[0062] Proimmune Human Donor T Cell Proliferation Assay The Proimmune study highlighted two regions of high antigenicity and two regions of moderate antigenicity. Highly antigenic: Domain Residue Range Sequence SpCBM 236~250 KGRVRLYVNGVLSRT PaTD 392~406 GAQVEVGSLNIRLGT Moderately antigenic: Domain Residue Range Sequence SpCBM 167~181 FYNLFSVSSATKKDE PaTD 338~352 SDWFSVSSNSLYTLS
[0063] ProPred in silico analysis Further in silico tools, online ProPred server 4 The results from the ProPred server are shown in Figure 1. The relative locations of the Nordic Biopharma / Proimmune epitopes are also highlighted, showing reasonable agreement between the three methods. In addition to the epitopes listed above, ProPred strongly predicted one other immunogenic epitope in the SpCBM domain. Domain Residue Range Sequence SpCBM 286~294 IRNLTVYNR Mutations in individual CBM and TD domains To guide the design of mutations that would reduce immunogenicity, ProPred was used to test the effect of changing every residue in these peptides to an alternative residue. Those that most reduced the predicted number of allele binders were identified. Because the crystal structures of both the SpCBM and TD domains are known, these mutations were also modeled to reduce the chance of introducing mutations that would clearly disrupt the protein structure.
[0064] Initially, nine single mutations were introduced into SpCBM and four single mutations into PaTD, which are listed below ("Im" stands for immunogenic mutant). TIFF2024163117000003.tif69153 NOTE: Im1–Im14 (not shown) were introduced by mutagenesis into a non-codon-optimized background before Proimmune data became available. Synthesis of WT and mutant constructs Genes encoding WT SpCBM, WT PaTD and variants Im15-Im27 were codon-optimized for E. coli expression and synthesized by GeneArt, which then cloned in-house into the pHISTEV vector for expression as 6His-tagged proteins.
[0065] Expression and biophysical characterization Initial expression studies were performed to assess solubility. Results indicate that although all were expressed, not all were soluble (Figure 2). Note: solubility (or lack thereof) is not necessarily a predictor of usefulness. Those skilled in the art will understand that when manufacturing or producing proteins, certain processes require the use of insoluble material because it is easily purified (from inclusion bodies and the like). Downstream protocols may then remodel the protein to modulate characteristics such as solubility.
[0066] The results of the expression studies show that: Im16(L170A) is insoluble or very poorly soluble Im25 (TD, S345D) is insoluble Im15(Y168W) and Im17(L170T) have reduced solubility · Im18 (V173G) and Im22 (I286A) are slightly decreased. The remainder show soluble expression. The 13 soluble proteins were expressed in E. coli and purified by immobilized metal affinity chromatography (IMAC) followed by TEV digestion to remove the 6His tag, then reverse IMAC and size exclusion chromatography (SEC).
[0067] The 10 purified domains (WTSp, Im19, Im20, Im21, Im22, Im23, WTTD, Im24, Im26 and Im27) were further characterized by: (i) Thermofluor for measuring melting temperature (Tm) (ii) Near-UV circular dichroism (CD) to compare the tertiary structure with WT (iii) Dynamic Light Scattering (DLS) to investigate the oligomer state in solution (iv) Surface Plasmon Resonance (SPR) to measure binding affinity to sialyllactose (v) Measurement of IL-8 cytokine stimulation
[0068] The results are summarized in Table 1. [Table 1] Table 1. Qualitative summary of biophysical characterization of WT domains and their variants. Color coding is from green to red (including green', orange and yellow), where green indicates that the variant is closely similar to its WT counterpart for that particular feature, and light green (green') or yellow indicates an increasing degree of difference. Red or orange indicates significant differences. N / A: These characterizations were not performed due to insufficient protein solubility / purity. N / D: Not determined.
[0069] Sp peptides 167-181: Im15, Im16, Im17, and Im18 are all insoluble or poorly soluble (as noted, this does not necessarily affect the utility of the protein). They lie in the "moderately" antigenic region 167-181 (FYNLFSVSSATKKDE), a region that is apparently highly amenable to change. Previous results indicate that M156F adjacent to L170 (and I286) increases the Tm by approximately 4°C. Therefore, it could be combined with L170T. M156F does not increase the predicted immunogenicity.
[0070] M185I increases the Tm by 5°C, paralleling L170 (Figure 3). This mutation could also be included. Note that, like M156F, M185I does not increase predicted immunogenicity but does slightly decrease the number of predicted allele binders. Sp peptide 236-250: Im19, Im20, and Im21 all behaved similarly to WT. They are located in the "highly" antigenic region 236-250 (KGRVRLYVNGVLSRT). Im19 (V239A) was chosen over the threonine mutation (Im20, V239T). Although there is no difference in predicted immunogenicity, Im19 is more consistent with the WT Thermofluor Tm and near-UV spectrum. This will be combined with Im21 (V246G).
[0071] Sp peptides 286-294: Im22(I286A) is broadly similar to WT, whereas Im23(Y292E) appears to exhibit lower ligand affinity. This region, 286-294IRNLTVYNR, was not flagged by Proimmune but is strongly predicted to be immunogenic by ProPred. There are several indications that Im22 has a lower Tm than WT. This residue is adjacent to M156 and may therefore behave differently if M156F is included.
[0072] TD peptides 338-352: Im24(S342D) and Im26(L348D) show similar characteristics to the WT trimerization domain, but some indication of a reduced Tm for Im26. They lie in the "moderately" antigenic region 338-352SDWFSVSSNSLYTLS. The WT sequence was predicted to bind nine alleles, whereas Im24 predicts two alleles and the Im24 / Im26 double mutant predicts one allele. TD peptides 392-406: Im27(R403K) is similar to WT. It is part of the "highly" antigenic region 392-406GAQVEVGSLNIRLGT. With this mutation, the predicted alleles are reduced from 21 to 3.
[0073] Synthesis of Im28-34, a combination of multiple mutations The following mutations were introduced: i) M156F / L170T ii) M156F / L170T / M185I: In ProPred, the predicted alleles for this region are reduced from 31 in WT to 19 in this combination. iii) V239A / V246G: In ProPred, the alleles for this region are reduced from 44 to 3. iv) I286A / Y292E: In ProPred, the allele is reduced from 41 to 1. v) V239A / V246G / I286A / Y292E combines the previous two preceding ones. vi) M156F / L170T / M185I / V239A / V246G / I286A / Y292E combines all Sp mutations vii) TD: S342D / L348D / R403K: The predicted alleles are reduced from 9 to 1 for TD peptide 338-352 and from 21 to 3 for peptide TD peptide 392-406. This triple mutant combines all TD mutants, all of which are surface exposed and distal to the N-terminus of the TD and would not be expected to interfere with the hexameric form of SpCBM.
[0074] The construct is referred to as Im28-Im34. (SpCBM) variant mutation Im28 M156F / L170T Im29 M156F / L170T / M185I Im30 V239A / V246G Im31 I286A / Y292E Im32 V239A / V246G / I286A / Y292E Im33 M156F / L170T / M185I / V239A / V246G / I286A / Y292E (PaTD) variant mutation Im34 S342D / L348D / R403K 2.5 Expression and biophysical characterization of Im28–Im34 Similar to the single mutations, the combination Im28-Im34 was synthesized by GeneArt and subcloned into pHISTEV for expression analysis. Nickel bead pulldowns against His-tagged soluble extracts were also performed (Figure 4).
[0075] Hexameric type Design of hexameric constructs HEX1-HEX17 Genes encoding the hexameric forms (designated HEX1 to HEX17) were synthesized by GeneArt. Sp2CBMTD TIFF2024163117000005.tif69156
[0076] To circumvent the problems associated with synthesizing repeats of tandem CBM copies, the hexameric form was synthesized in two parts: the first gene contained the first CBM and the second part encompassed the second CBM plus TD. These could then be cloned simultaneously into pHISTEV to create the Sp2CBMTD construct that formed a trimer upon expression. The first hexamer, HEX1, contained the mutations L170T / V239A / V246G / I286A / Y292E in the CBM and S342D / L348D / R403K in the TD. Solubility data for the individual domains indicated that HEX1 was unlikely to be soluble (again, not necessarily reflective of the utility of the molecule). A further construct, HEX3, was synthesised, which contained the same mutations as HEX3, but with the addition of Y292E.
[0077] HEX3 was synthesized and subcloned into pHISTEV vector. Expression was insoluble under all tested conditions (varying temperature, IPTG concentration, cell density at induction, with or without heat shock). The CBM-only domain containing the same three mutations (V239A V246G I286A) is soluble. The double mutant (V239A V246G) behaves very similarly to WT. Therefore, further variants (HEX4, HEX5 and HEX6) without I286A and containing either one or both TD mutations were designed and constructed by PCR / ligation. During work on HEX6, several other versions were designed containing different combinations of HEX6 mutations (numbered HEX7 to HEX16; uncharacterized). HEX17 contains the HEX6 mutation along with an additional A162P mutation. This proline mutation was shown to increase the single CBM Tm by 3-4°C. The proline mutation is not close to other mutations, the N- or C-terminus, or the ligand binding site.
[0078] Characterization of hexameric variants The expression, purification and characterization results are shown in Table 2. Based on these results, HEX6 and HEX17 were moved forward. The location of the HEX17 mutation on the hexamer is shown in Figure 5. [Table 2] Table 2. Qualitative overview of the biophysical characterization of hexameric Sp2CBMTD variants. Color coding is green to red, where green indicates that the variant is closely similar to its WT counterpart for that particular feature, and light green (green') or yellow indicates an increasing degree of difference. Red or orange indicates significant differences. N / A: These characterizations were not performed due to insufficient protein solubility / purity. N / D: Not determined. EXAMPLES
[0079] Example 1 Inflammatory mediators. Objective: To evaluate the innate immune response of mCBM-treated human lung epithelial cells (A549) by analyzing the levels of inflammatory mediators over time. Administration of Sp2CBMTD to mammalian cells stimulated a pro-inflammatory response both in vitro and in vivo 1、2 To determine whether this was still observed with engineered hexameric sialic acid binding molecules, mammalian A549 cells were stimulated by the addition of 10 μg of biologics (Sp2CBMTD (also known as SpOrig), HEX6 or HEX17) and cell culture medium was harvested at specific time points after administration. The concentrations of inflammatory mediators were measured by both ELISA and multiplex assays. Human IL-8 (reference cytokine for testing) response using Human 1xMouse CXCL1 / KC Quantikine ELISA Kit (R&D BioSystems). IL-8 concentration levels from stimulated A549 cells are shown in Figure 6. It is clear that when A549 cells are stimulated with modified hexamer HEX17, IL-8 levels are significantly lower than when compared to Sp2CBMTD (also known as SpOrig), or HEX6 stimulated cells.
[0080] Inflammatory mediator responses using human Cytokine 12-plex assay (Bio-Plex Pro™, Bio-Rad). Figure 7 shows the analysis of 12 inflammatory mediators from culture media at specific time points (6h, 24h, 48h) following A549 cell stimulation with Sp2CBMTD (WT, also known as SpOrig), HEX6 and HEX17 (variants). Prior to analysis, samples were thawed and diluted 1:4 in PBS before using the human HS Cytokine-12 plex assay (R&D Systems). The data show that: HEX17 affects the levels of almost all cytokines tested compared to SpOrig and HEX6, with significantly lower observed concentrations (pg / ml) of the analytes IL-6, IL-8, GM-CSF and IFN-gamma at 48 h compared to SpOrig and HEX6. When compared to controls at 48 h, HEX17 appeared to increase levels of all cytokines tested except IL-5 and VEGF (yet to be confirmed). HEX6 only showed reduced IL-6 stimulation compared to SpOrig at 48 h.
[0081] Example 2 In vivo PR8 mouse data. The aim of the study was to evaluate the efficacy of Sp2CBMTD (SpOrig) and its variants in a mouse model of lethal influenza infection. Each candidate protein was also administered in the absence of influenza infection to assess whether it alone caused morbidity or mortality.
[0082] Survival, clinical scores and weight loss. The results show that neither CBM2 (HEX17), CBM3 (HEX6) nor CBM4 (WT, SpOrig) alone caused any overt morbidity or mass mortality. Administration of a single 100 μg dose of either CBM2 (HEX17), CBM3 (HEX6) and CBM4 (WT, SpOrig) 1 day prior to lethal challenge with PR8 influenza virus protected against PR8 infection, with the greatest efficacy seen with HEX17 (100% survival), followed by SpOrig and then HEX6 (Figure 8). Clinical scores were also lower with HEX17 compared to SpOrig and HEX6 (Figure 9). All surviving mice in the single high dose treatment group lost weight at peak infection but quickly recovered in contrast to untreated infected mice (Figure 10).
[0083] Anti-mCBM antibody analysis of lung homogenates and serum tissues from the PR8 challenged mouse study. The aim of this study was to determine whether the modified immunogenic epitopes of the modified variants of Sp2CBMTD (SpOrig) could show reduced antibody levels in mice in the PR8 challenge (it should be noted that the epitopes were modified based on human MHC class II binding information). In this regard, mice surviving the PR8 challenge were selected on day 21, and lungs and serum were collected and tested for anti-mCBM antibodies, IgG, IgA, IgE and IgM against the coated antigen SpOrig (1 μg / well) in an ELISA format. The data shown in FIG. 11 showed that: The engineered protein HEX17 showed a significant (p<0.05) reduction in mouse lung IgM levels compared to SPORIG. Since only one mouse survived for HEX6 treatment, only the data for HEX17 and SpOrig were statistically analyzed. · There is some indication of a slight trend towards lower antibody levels (lung IgA and IgM) in mice treated with modified CBM compared to SpOrig.
[0084] Example 3 Effects of repeated intranasal dosing of mCBM, Sp2CBMTD and HEX17 in mice. The objective of this study was to evaluate the clinical impact and immune responses of repeated dosing of both Sp2CBMTD (SpOrig) and HEX17 over time in mice. Experimental procedure Intranasal dosing. On days 1, 15 and 29, groups of mice (10 female and 10 male BALB / c mice per drug) were administered 20 μg of either sterile PBS, Sp2CBMTD or HEX17 by the intranasal route under reversible gas anesthesia (isoflurane / oxygen mixture) in a fixed volume of 40 μL. Body weight and post-dosing observations. All mice were weighed twice weekly from day -1 until the end of the study (day 35). Post-dosing observations were recorded every 15 min for the first 2 h after dose administration, then every 30 min for the next 6 h.
[0085] Analysis of tissue samples. Mouse tissues (serum and bronchoalveolar lavage (BAL)) were tested for anti-CBM antibody responses (IgG, IgA, and IgM) against either Sp2CBMTD or HEX17 (1 μg / well) as coating antigen in an ELISA format. The OD of each sample after reaction of HRP-conjugated detection antibodies against the various antibody types with its chromogenic substrate 3,3',5,5'-tetramethylbenzidine (TMB) was 0.01. 450nm Absorbance reading at (reference background OD 620nm ) was measured.
[0086] result: Clinical scores. Further testing of the effects of repeated intranasal dosing of Sp2CBMTD and HEX17 in mice revealed that neither molecule had any significant effect on body weight or food intake. Furthermore, at later doses, HEX17 appeared to be better tolerated, and some (reversible) clinical signs (including piloerection, hunched posture, hypoactivity, half-closed eyes, and irregular breathing) were observed for a limited period after Sp2CBMTD administration.
[0087] Anti-mCBM antibody analysis of mouse serum and BAL tissues. The data shown in Figure 12 showed that when mice were given three doses of 20 μg of CBM every two weeks between days 1 and 29, adaptive immune responses were elicited against both CBMs after 35 days. HEX17 (an example of a modified or "deimmunized" CBM whose epitopes have been modified based on human MHC class II binding information previously demonstrated) demonstrated a significant (p<0.05) reduction in IgA compared to Sp2CBMTD-treated mice in both BAL and serum tissues. This was observed against both coated antigens. The difference in IgA responses between the two candidates was also striking between male and female mice. The difference in IgG responses was more evident in BAL samples than serum. There was also a significant reduction in IgM levels in both BAL and serum samples when tested against Sp2CBMTD, but this was not significant with HEX17-coated plates.
Claims
1. A sialic acid binding molecule comprising one or more modified family 40 carbohydrate binding modules (CBM40).
2. The sialic acid binding molecule of claim 1 , wherein one or more modified CBM40s contain one or more mutations relative to a reference sequence.
3. The reference sequence is (i) wild-type family 40 CBM sequence; (ii) the wild-type CBM40 sequence of Vibrio cholerae; (iii) the NanH sialidase sequence of Vibrio cholerae; (iv) the wild-type CBM40 sequence of Streptococcus pneumoniae; (v) the NanA sialidase sequence of Streptococcus pneumoniae; (vi) the sequence of SEQ ID NO:1; (vii) the sequence of SEQ ID NO:2; (viii) the sequence of SEQ ID NO:3; and (ix) a sequence of SEQ ID NO: 4 The sialic acid binding molecule of claim 1 or 2, selected from the group consisting of:
4. The mutation, (i) one or more amino acid substitutions; (ii) removal of one or more amino acids; (iii) one or more amino acid additions / insertions; (iv) one or more amino acid / sequence inversions; and (v) one or more amino acid / sequence overlaps The sialic acid binding molecule according to any one of claims 1 to 3, selected from the group consisting of:
5. The sialic acid binding molecule of any one of claims 1 to 4, wherein the sialic acid binding molecule comprises an engineered oligomerization domain.
6. The sialic acid binding molecule of claim 5 , wherein the modified oligomerization domain comprises one or more mutations relative to a reference sequence.
7. The reference sequence is (i) the wild-type Pseudomonas aeruginosa pseudoaminidase sequence; (ii) the Pseudomonas aeruginosa pseudoaminidase amino acid sequence deposited under accession number Q9L6G4; (iii) the sequence of SEQ ID NO: 13; and (iv) the sequence of SEQ ID NO: 14 The sialic acid binding molecule of claim 5 or 6, selected from the group consisting of:
8. The structure: CBM1(V239A V246G A162P)--CBM2(V239A V246G A162P)--TD(S342D R403K) The sialic acid-binding molecule of any one of claims 1 to 7, comprising: CBM1 and CBM2 derived from the CBM40 sequence; and TD derived from the trimerization domain.
9. A sialic acid binding molecule comprising the following sequence: GAMVIEKEDVETNASNGQRVDLSSELDKLKKLENATVHMEFKPDPKAPAFYNLFSVSSATKKDEYFTMAVYNNTATLEGRGSDGKQFYNNYNDAPLKVKPGQWNSVTFTVEKPTAELPKGRA RLYVNGGLSRTSLRSGNFIKDMPDVTHVQIGATKRANNTVWGSNLQIRNLTVYNRALTPEEVQKRSGGGSGGVIEKEDVETNASNGQRVDLSSELDKLKKLENATVHMEFKPDPKAPAFYNLF SVSSATKKDEYFTMAVYNNTATLEGRGSDGKQFYNNYNDAPLKVKPGQWNSVTFTVEKPTAELPKGRARLYVNGGLSRTSLRSGNFIKDMPDVTHVQIGATKRANNTVWGSNLQIRNLTVYN RALTPEEVQKRSGGSLGVPDFESDWFDVSSNSLYTLSHGLQRSPRRVVVEFARSSSPSTWNIVMPSYFNDGGHKGSGAQVEVGSLNIKLGTGAAVWGTGYFGGIDNSATTRFATGYYRVRAWI
10. (i) For treatment (ii) for the treatment and / or prevention of a disease in a subject in need thereof; (iii) in modulating the immune response (in a human or animal subject); (iv) for regulating cell growth, proliferation and / or differentiation (v) as an adjuvant; (vi) as a medicine; (vii) for the treatment of cancer; and (viii) for the treatment and / or prevention of diseases caused or contributed to by pathogens which bind to cell surface sialic acid-containing receptors; A sialic acid binding molecule according to any one of claims 1 to 9 for use.
Citation Information
Patent Citations
Immunomodulatory compound
JP2017505340A
Modified proteins
JP2021511308A
